Skip to search formSkip to main contentSkip to account menu

everolimus 5 MG Tablet for Oral Suspension [Afinitor]

Known as: Afinitor Disperz 5 MG Tablet for Oral Suspension, EVEROLIMUS 5 mg ORAL TABLET, FOR SUSPENSION [Afinitor Disperz] 
National Institutes of Health

Related topics

Related topics

9 relations
Butylated HydroxytolueneCrospovidoneLactose MonohydrateMagnesium stearate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
BACKGROUND Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine… 
2016
2016
Neue Therapieoptionen bei Neuroendokrinen Tumoren des Gastrointestinaltraktes
Recent therapy options of gastro- intestinal neuroendocrine tumours. Neuroen- docrine tumors (NET) of gastroenteropancreatic (GEP… 
2016
2016
Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells
BackgroundmTOR inhibition of aromatase inhibitor (AI)-resistant breast cancer is currently under evaluation in the clinic… 
2015
2015
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
Everolimus (RAD001, Afinitor®) is an oral, selective mTOR inhibitor recently approved by the US-FDA in combination with… 
Review
2013
Review
2013
Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Oral everolimus (Afinitor®) in combination with exemestane is indicated for the treatment of hormone receptor-positive, human… 
Review
2013
Review
2013
Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors
Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR), an intracellular protein kinase… 
2012
2012
FDA Approves Everolimus (Afinitor Disperz) for Rare Pediatric Brain Tumor
The FDA approved a dissolvable form of everolimus (Afinitor Disperz) for the treatment of children with subependymal giant cell… 
2012
2012
Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are…
In Austria, about 24% of women with initially diagnosed breast cancer (BC) have locally advanced and about 5% have metastatic… 
2009
2009
Everolimus (Afinitor®), Trastuzumab (H), and Paclitaxel (P) or Vinorelbine (V) in the Treatment of HER-2+ Metastatic Breast Cancer (MBC) Patients (Pts) Pre-Treated with Lapatinib-Containing Therapy…
Introduction: The re-introduction of H-based therapy after progression on a lapatinib-containing regimen has not yet been… 
2009
2009
Everolimus (Afinitor®) for advanced/metastatic kidney cancer
The purpose of this report was to evaluate efficacy and safety of second-line therapy with everolimus, an mTOR inhibitor, for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License